GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of dose escalation — my 2-week log, condensed into one table — 58 comments in the full submission. View in context.
1.7k
c/retatrutide·submitted 6 months ago by u/yara_lindholm

dose escalation — my 2-week log, condensed into one table

Questionbranch of 8 comments

Posting this as a discussion rather than a claim: dose escalation — my 2-week log, condensed into one table. Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring…

Read the full submission and all 58 comments →

This branch

8 comments, started 6 months ago
u/isabela_nilsen276 points·6 months ago

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.

replysharereportpermalink
u/yara_lindholmOP200 points·6 months ago

Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.

replysharereportpermalink
u/source_or_silence160 points·6 months ago

dose escalation in the trials was slow for a reason

replysharereportpermalink
u/yusuf_ramos68 points·6 months ago

The fatigue profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.

replysharereportpermalink
u/zeynep_mbeki112 points·6 months ago·edited

Kept a log specifically because there is so little published. It is one person and it is not data.

replysharereportpermalink
u/trialwatch_theotrial nerd93 points·6 months ago

the energy-expenditure story is mechanistically interesting and clinically unproven

replysharereportpermalink
u/injection_site_iris36 points·6 months ago

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

replysharereportpermalink
load more comments (1) →

← back to the whole thread

About c/retatrutide

Retatrutide: GIP/GLP-1/glucagon triple agonism, the TRIUMPH programme, and the fact that most people discussing it are handling research-grade material with no human-use approval anywhere. Dose-response, heart-rate signal, and the unusually steep phase-2 weight curves get argued about here weekly.

65kmembers
130submissions
Sep 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/retatrutide rules
  1. Retatrutide is not approved anywhere for human use. Posts must not read as usage instructions.
  2. Phase 2 numbers are not maintenance numbers. Cite the trial and the dose arm.
  3. Heart-rate and dose-escalation reports need actual measurements, not impressions.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.